Q: I am fortunate to be up 50% on my CM stock. Looking forward I am wondering which of the big six banks have the best growth potential. I am thinking that CM has a more limited growth potential after such a big move, but I also have been trying to resist the urge to sell stocks with good gains. Your input would be helpful. Note that taxes are not a concern- the shares are in an RRSP.
You can view 3 more answers this month. Sign up for a free trial for unlimited access.
Investment Q&A
Not investment advice or solicitation to buy/sell securities. Do your own due diligence and/or consult an advisor.
Q: For capital appreciation which of these 2 stocks would you prefer for a two year hold?
Thx
Thx
Q: Thoughts please on Mr. Nyland of Lumine being appointed to their board?
Thx
Thx
Q: Hello 5i Team
Finally Melcor Developments (MRD) has offered to take Melcor REIT (MR-UN) private at $4.95 with a closing date of late Q4 2024.
I note there is a one month "go shop" for MR-UN to possibly find a better deal, however with MRD owing ~55 %; MRD being the manager of the REITs properties; and the year long Strategic Review Process - is it even a possibility that MR-UN could find another buyer?
With MR-UN trading ~$4.80 should I sell my holdings and move onto another REIT? With only a 3 % difference I think there are other opportunities in the REIT space to replace MR-UN.
What would be 5i top names in the REIT space to replace MR-UN (can be a different sub-sector from MR-UN's operations).
Thanks
Finally Melcor Developments (MRD) has offered to take Melcor REIT (MR-UN) private at $4.95 with a closing date of late Q4 2024.
I note there is a one month "go shop" for MR-UN to possibly find a better deal, however with MRD owing ~55 %; MRD being the manager of the REITs properties; and the year long Strategic Review Process - is it even a possibility that MR-UN could find another buyer?
With MR-UN trading ~$4.80 should I sell my holdings and move onto another REIT? With only a 3 % difference I think there are other opportunities in the REIT space to replace MR-UN.
What would be 5i top names in the REIT space to replace MR-UN (can be a different sub-sector from MR-UN's operations).
Thanks
Q: Hello 5i, as there is a takeover offer for Melcor REIT could you offer an opinion as to is the offer a fair price for current shareholders and the possibility of a competing take over offer.
-
TECSYS Inc. (TCS)
-
Super Micro Computer Inc. (SMCI)
-
Badger Meter Inc. (BMI)
-
Docebo Inc. (DCBO)
-
Vertiv Holdings LLC Class A (VRT)
-
Nextracker Inc. (NXT)
Q: For each pair, which would you choose today? VRT vs. SMCI, DCBO vs. TCS, NXT vs. BMI. Thank you!
Q: Hello 5i
Do you know of an ETF that tracks the TSX30?
Thank you
Dave
Do you know of an ETF that tracks the TSX30?
Thank you
Dave
Q: Share this news no queston
MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its expectations, which necessitates that Moberg inform the market about this fact.
Moberg's full press release can be found here.
Cipher owns the Canadian marketing rights to Moberg's MOB-015 through a licensing agreement (the "Agreement") dated September 18, 2018, to commercialize, promote, sell and distribute the product exclusively in Canada. On signing the Agreement, the Company paid an upfront amount of US$0.5 million and any future additional payments of up to US$14.1 million are contingent upon successful achievement of certain clinical data results as well as development, regulatory and commercial sales milestones. Cipher has no further financial obligations in respect of the Agreement if the applicable development and regulatory milestones outlined in the Agreement are not attained.
The Company will continue to collaborate with its partner Moberg as full results from their clinical trial become available, however this pipeline product does not impact the sales and earnings profile of Cipher's existing business today.
The Company continues to be focused on its recent acquisition of the NatrobaTM business from ParaPRO LLC as announced on July 29, 2024, as well as other potential growth opportunities. The Company believes the growth potential for the NatrobaTM product in the U.S. market and other markets internationally is significant, and the integration of this business into its existing profitable North American platform remains Cipher's focus and priority in the near term.
MISSISSAUGA, ON, Sept. 13, 2024 /CNW/ - Cipher Pharmaceuticals Inc. (TSX: CPH) (OTCQX: CPHRF) ("Cipher" or the "Company") announced today that its partner, Moberg Pharma AB ("Moberg"), issued a news release earlier today stating that it has received information about clinical cure in a subset of patients in the ongoing North American Phase 3 study for MOB-015, a product for the treatment of nail fungus. Moberg has noted that the number of patients who have achieved clinical cure in this blinded subset of patients is lower than its expectations, which necessitates that Moberg inform the market about this fact.
Moberg's full press release can be found here.
Cipher owns the Canadian marketing rights to Moberg's MOB-015 through a licensing agreement (the "Agreement") dated September 18, 2018, to commercialize, promote, sell and distribute the product exclusively in Canada. On signing the Agreement, the Company paid an upfront amount of US$0.5 million and any future additional payments of up to US$14.1 million are contingent upon successful achievement of certain clinical data results as well as development, regulatory and commercial sales milestones. Cipher has no further financial obligations in respect of the Agreement if the applicable development and regulatory milestones outlined in the Agreement are not attained.
The Company will continue to collaborate with its partner Moberg as full results from their clinical trial become available, however this pipeline product does not impact the sales and earnings profile of Cipher's existing business today.
The Company continues to be focused on its recent acquisition of the NatrobaTM business from ParaPRO LLC as announced on July 29, 2024, as well as other potential growth opportunities. The Company believes the growth potential for the NatrobaTM product in the U.S. market and other markets internationally is significant, and the integration of this business into its existing profitable North American platform remains Cipher's focus and priority in the near term.
-
TMX Group Limited (X)
-
goeasy Ltd. (GSY)
-
Propel Holdings Inc. (PRL)
-
Brookfield Corporation Class A Limited Voting Shares (BN)
-
Brookfield Asset Management Ltd. Class A Limited Voting Shares (BAM)
-
Hamilton Canadian Financials YIELD MAXIMIZER TM ETF (HMAX)
Q: Holding the following Financial sector stocks: BAM, BN, BNS, GSY, PRL, SLF, TD, X for a total of 20% in TFSA & RIF combined. Would like to reduce # of holdings to 5 or 6 and Financial % to about 15% . Your comments/suggestions/alternatives on the following setup would be appreciated:
RIF = HMAX, BAM, X
TFSA = BN, GSY (or BN, PRL or BN, PRL, GSY??)
As always, thank you for helping to provide clarity.
RIF = HMAX, BAM, X
TFSA = BN, GSY (or BN, PRL or BN, PRL, GSY??)
As always, thank you for helping to provide clarity.
-
iShares Diversified Monthly Income ETF (XTR)
-
iShares Core MSCI Canadian Quality Dividend Index ETF (XDIV)
-
Hamilton Canadian Financials YIELD MAXIMIZER TM ETF (HMAX)
Q: In a non-registered account give me your pick in preference order HMAX or XTR or XDIV? Thanks so much.
Q: Hi Team,
after today's decline in DRX that seems overdone I am thinking to initiate a position in DRX. I am very tempted to sell my NFI stake and make the switch for shares of ADF Group. What would you think of the move and would you have any other suggestions to replace NFI in my Portfolio.
after today's decline in DRX that seems overdone I am thinking to initiate a position in DRX. I am very tempted to sell my NFI stake and make the switch for shares of ADF Group. What would you think of the move and would you have any other suggestions to replace NFI in my Portfolio.
-
Brookfield Infrastructure Partners L.P. (BIP.UN)
-
Brookfield Infrastructure Corporation Class A Exchangeable Subordinate Voting Shares (BIPC)
Q: I bought BIP.UN in a registered account about a year ago. Looking back, I would have been better to buy BIPC.
Looking forward ie over the long term, do you think that BIPC will continue to outperform on a total return basis?
Looking forward ie over the long term, do you think that BIPC will continue to outperform on a total return basis?
Q: Hi there,
I’m a long term holder of NPI, of course it’s been very weak along with the renewable sector. Last several days it’s showing some life.
Is it just general movement with rest of the utilities in anticipation of lower interest rates or is there something else? Longer term HOLD ie. +3-5 years (also own CPX).
Thanks a lot!
I’m a long term holder of NPI, of course it’s been very weak along with the renewable sector. Last several days it’s showing some life.
Is it just general movement with rest of the utilities in anticipation of lower interest rates or is there something else? Longer term HOLD ie. +3-5 years (also own CPX).
Thanks a lot!
Q: TVK at $98+! Similar to an earlier question, is the valuation getting stretched at this point, or is it worth jumping in a bit? Given the current circumstances, what would be a good entry point price in your view? Thank you!
Q: Hi Peter, I've held EGLX since 2021 in my RRSP and my cost is 3.91 ( haha good for me) it's hard to let it go especially because it's in my RRSP. Is there even a chance of a slight recovery, takeover, if so what could they offer for it, or is it time to bite the bullet and sell. Thanks
Q: I wanted to push back a little on the last answer. You noted they have high debt. The release said they have over 200 million cash and no external debt. Also you referred to eps next year as dropping to 2020 levels. The company started in late 2022 and I see forecasts as growing. I do agree the sentiment is horrible and I believe it is tied to the short position and tactics. However I really think this is a great buying opportunity when this stops dropping and settles at an ridiculous level. I was hoping you would agree.
Q: Please comment on latest Q results,company & going forward.A 9% haircut in after hours in response to Q results.Add,Hold or sell?Txs for U usual great services & views
Q: Brookfield to invest up to US$1.1-billion in sustainable fuels provider Infinium....hi I cannot seem to get info for Infinium.. can u provide some info re investing in the company and the symbol for trading thanks...Maureen
Q: Hi Team,
I do not own Tvk yet, mostly being hesitant that it would be tied to the oil and gas sector too much which is highly cyclical and I now mostly avoid resource stocks after being burned in the past. However Tvk has not fallen with the recent downturn in Canadian oil stocks. Still riding new highs daily here it seems. I guess my question is do you see a lag effect coming here in possible weakness coming for Tvk being that the oil sector is once again getting hit? Or is it diversified enough to completely avoid this? I am wondering if a better entry point might present itself down the road a quarter or 2? The
Thanks ,
Shane
I do not own Tvk yet, mostly being hesitant that it would be tied to the oil and gas sector too much which is highly cyclical and I now mostly avoid resource stocks after being burned in the past. However Tvk has not fallen with the recent downturn in Canadian oil stocks. Still riding new highs daily here it seems. I guess my question is do you see a lag effect coming here in possible weakness coming for Tvk being that the oil sector is once again getting hit? Or is it diversified enough to completely avoid this? I am wondering if a better entry point might present itself down the road a quarter or 2? The
Thanks ,
Shane
Q: What is the best covered call option ETF in your option today?